1. Variant sequences main allergen Malus domectica Mal d 1 dm (SEQ ID NO: 1) or its isoforms for use in the immunotherapy of patients allergic to pollens Malus domectica and / or Betula verrucosa, identical with SEQ ID NO: 1 of at least 95%, preferably at least 97%, said embodiment thus characterized in that: a) it exhibits reduced IgE reactivity compared with said allergen Mal d 1 (SEQ ID NO: 1) b) it has an amino acid sequence in which, when aligned with SEQ ID NO: 1 contains at least one, preferably two substitutions residues Asp and / or Asn, corresponding to positions 25 and 78, SEQ ID NO: 1.2. Sequence variant of claim 1, wherein the IgE reactivity of sera from patients with allergies to Malus domectica and / or pollen Betula verrucosa, reduced by at least 10% compared with Mal d 1 allergen SEQ ID NO: 1.3. Variant sequences according to claims 1 and 2, wherein both of the residues Asp and Asn zamescheny.4. Sequence variant of claim 3, wherein: - the residue Asp 25 replaced by neutral polar, or basic amino acid, which is preferably selected from Ala, Thr, Gly, Pro, Leu, Ile, Ser, Phe, Lys and Arg, more preferably from Ala , Thr, Ser, Gly, Lys and Arg - residue Asn 78 replaced with a neutral, acidic or basic amino acid which is preferably selected from Ala, Gly, Pro, Leu, Ile, Phe, Lys, Arg, Asp and Glu, and more preferably from Ala, Gly, Lys, Arg, Asp and Glu.5. Variant sequences according to claims 1 and 2, consisting of SEQ ID NO: 2.6. A fusion protein for use in the immunotherapy of patients allergic to pollens Malus domectica and / or Betula verrucosa, comprising a main sequence variant Malus domectica allergen, as defined in claims 1-5 and hypoallergenic variant main allergen Bet v 11. Вариант последовательности главного аллергена Malus domectica Mal d 1 дт (SEQ ID NO:1) или его изоформы для применения в иммунотерапии пациентов, подверженных аллергии к пыльце Malus domectica и/или Betula verrucosa, идентичный с SEQ ID NO:1 по меньшей мере на 95%, предпочти
